Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndromes
Clinical trials
Clinical trial participation is an individual, and important, decision. Clinical trials are designed to test new medications in people. Clinical trials may involve a placebo group (inactive ‘medicine’) to see if the new medication offers an advantage over current standard treatment. Some trials are ‘open label’, in which all participants receive active medications or experimental treatment.
There are many advantages to participating in clinical trials. Participants in clinical trials at a minimum receive current standard care for their disease from medical teams experienced with the disease. Clinical trials also offer the opportunity to try a new medication long before it is approved by the Food and Drug Administration.
If you choose to participate in a clinical trial, you have the right to understand fully what is expected of you, what the trial will involve and the potential risks to your health. You also have the right to withdraw your consent to participate at any time. Learn more about clinical trials at www.clinicaltrials.gov.
Trials That May be of Interest to Our Members
HES Trials
Clinical Trials for Idiopathic HES
Hypereosinophilic Syndrome Trials
An etiological role for aeroallergens and eosinophils in experimental esophagitis.
Intravenous Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES)
This study was a randomized, double-blind, placebo controlled study to evaluate corticosteroid-reduction and – sparing effects of mepolizumab in subjects with Hypereosinophilic Syndrome (HES) and to evaluate the efficacy and safety of mepolizumab in controlling the clinical signs and symptoms of HES over nine months.
This trial has closed for recruitment and is now completed. An open-label follow-on protocol to further evaluate the administration of mepolizumab in the patients with HES who participated in the randomised placebo-controlled trial is fully recruited and ongoing.
|
